Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Canadian Natural Resources Ltd. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.57 (market cap $5.07B), while Canadian Natural Resources Ltd. trades at $47.73 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 19.4× ACADIA Pharmaceuticals Inc.'s market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CNQ | |
|---|---|---|
Market Cap | $5.07B | $98.11B |
Sector | Health | Energy |
52-Week High | $29.41 | $50.55 |
52-Week Low | $20.06 | $29.31 |
Enterprise Value | $4.19B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Canadian Natural Resources (CNQ) trades at $47.845, up 1.26% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS beat estimates. The company shows robust profitability with a 22.87% net margin and 26.69% ROE, supported by record production and disciplined capital spending. Recent news highlights dividend reliability and operational strength, with analyst consensus heavily favoring buy ratings.
CNQ presents a compelling investment case with attractive valuation (P/E 11.82), consistent dividend payouts, and positive cash flow trends. Key risks include oil price volatility and rising debt levels, but the company's scale and efficiency underpin resilience. Wall Street optimism, with 27 buy ratings, suggests further upside potential amid stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
